The new discipline of ‘real-world data science’ has emerged over recent years. Expert practitioners in this embryonic field are finding their feet, not just in terms of role and remit, but also with regards to which questions they can answer and the methods they can bring to bear [1]. But why are pharmaceutical companies employing real-world data scientists and seeking real-world data opportunities on a scale not previously seen? The last two decades saw a similar explosion in organisations with specialist expertise in the delivery of randomised controlled trials (RCTs) and pharmacovigilance to the standards of licencing authorities that include the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pOyRly
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Purpose To test the effects of 4 weeks of unilateral low-load resistance training (LLRT), with and without blood flow restricti...
-
Abstract There are limited published data on the burden of rare cancers in the United States. By using data from the North American Associ...
-
Relativistic hydrodynamics has been quite successful in explaining the collective behaviour of the QCD matter produced in high energy heavy-...
-
36 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: quality...
-
by Claudia Zielke, Ondrej Kosik, Marie-Louise Ainalem, Alison Lovegrove, Anna Stradner, Lars Nilsson An extraction method for mixed-linkage...
-
The genital mucosa is a barrier that is constantly exposed to a variety of pathogens, allergens, and external stimuli. Although both allerge...
-
Abstract Purpose Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study,...
-
by Mark A. Valasek, Irene Thung, Esha Gollapalle, Alexey A. Hodkoff, Kaitlyn J. Kelly, Joel M. Baumgartner, Vera Vavinskaya, Grace Y. Lin, A...
-
The receptor tyrosine kinase KIT is an established oncogenic driver of tumor growth in certain tumor types, including gastrointestinal strom...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου